SAN DIEGO, Jan 21, 2010 (BUSINESS WIRE) -- Illumina, Inc. (NASDAQ:ILMN) today announced that it will issue results for fourth quarter and fiscal year 2009 following the close of market on Thursday, February 4, 2010.
On the same day, at 2:00pm Pacific Time (5:00pm Eastern Time), Jay Flatley, president and chief executive officer, and Christian Henry, senior vice president, Corporate Development, and chief financial officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results.
Conference Call Details:
The conference call will begin at 2:00pm Pacific Time (5:00pm Eastern Time) on Thursday, February 4, 2010. Interested parties may listen to the call by dialing 866.788.0546 (passcode: 47715520), or if outside North America, by dialing +1.857.350.1684 (passcode: 47715520). Individuals may access the live teleconference under the "Corporate/Investor Information" tab of Illumina's web site at http://www.illumina.com.
A replay of the conference call will be available from 5:00pm Pacific Time (8:00pm Eastern Time) on February 4, 2010 through February 11, 2010 by dialing 888.286.8010, or if outside North America, by dialing +1.617.801.6888 (passcode: 71521642).
About Illumina
Illumina (http://www.illumina.com) is a leading developer, manufacturer, and marketer of next-generation life-science tools and integrated systems for the large-scale analysis of genetic variation and biological function. Using our proprietary technologies, we provide a comprehensive line of products and services that currently serve the sequencing, genotyping, and gene expression markets, and we expect to enter the market for molecular diagnostics. Our customers include leading genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations, and biotechnology companies. Our tools provide researchers around the world with the performance, throughput, cost effectiveness, and flexibility necessary to perform the billions of genetic tests needed to extract valuable medical information from advances in genomics and proteomics. We believe this information will enable researchers to correlate genetic variation and biological function, which will enhance drug discovery and clinical research, allow diseases to be detected earlier, and permit better choices of drugs for individual patients.
Forward-Looking Statements
This release may contain forward-looking statements that involve risks and uncertainties. Important factors that could cause actual results to differ materially from those in any forward-looking statements are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release.
SOURCE: Illumina, Inc.
Illumina, Inc.
Investors:
Peter J. Fromen
Sr. Director, Investor Relations
+858-202-4507
pfromen@illumina.com
or
Media:
Wilson Grabill
Sr. Manager, Public Relations
+858-882-6822
wgrabill@illumina.com
